Surmodics Balance Sheet Health
Financial Health criteria checks 5/6
Surmodics has a total shareholder equity of $124.0M and total debt of $29.5M, which brings its debt-to-equity ratio to 23.8%. Its total assets and total liabilities are $182.8M and $58.9M respectively. Surmodics's EBIT is $18.5M making its interest coverage ratio 7.7. It has cash and short-term investments of $40.9M.
Key information
23.8%
Debt to equity ratio
US$29.48m
Debt
| Interest coverage ratio | 7.7x |
| Cash | US$40.94m |
| Equity | US$123.95m |
| Total liabilities | US$58.86m |
| Total assets | US$182.81m |
Recent financial health updates
We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17
Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Recent updates
Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
May 02We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Surmodics Non-GAAP EPS of -$0.34 beats by $0.04, revenue of $24.9M misses by $0.29M
Jul 27Estimating The Intrinsic Value Of Surmodics, Inc. (NASDAQ:SRDX)
Jul 22Is It Too Late To Consider Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 03Shareholders May Not Be So Generous With Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation And Here's Why
Feb 04Do Surmodics's (NASDAQ:SRDX) Earnings Warrant Your Attention?
Dec 24Estimating The Fair Value Of Surmodics, Inc. (NASDAQ:SRDX)
Aug 13When Should You Buy Surmodics, Inc. (NASDAQ:SRDX)?
Jun 09Is Now The Time To Put Surmodics (NASDAQ:SRDX) On Your Watchlist?
May 10Surmodics EPS misses by $0.01, beats on revenue
Apr 28How Much Are Surmodics, Inc. (NASDAQ:SRDX) Insiders Taking Off The Table?
Feb 05
Financial Position Analysis
Short Term Liabilities: SRDX's short term assets ($84.3M) exceed its short term liabilities ($19.2M).
Long Term Liabilities: SRDX's short term assets ($84.3M) exceed its long term liabilities ($39.7M).
Debt to Equity History and Analysis
Debt Level: SRDX has more cash than its total debt.
Reducing Debt: SRDX's debt to equity ratio has increased from 0% to 23.8% over the past 5 years.
Debt Coverage: SRDX's debt is well covered by operating cash flow (87.4%).
Interest Coverage: SRDX's interest payments on its debt are well covered by EBIT (7.7x coverage).